GlassScriptPhysician profile
Gregory M Flippo
NPI 1033187109
$5,768.10
in general payments reported to CMS, 2019-2025
57 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $1,231 · 2021: $1,811 · 2022: $444 · 2023: $612 · 2024: $457 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,509.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $820.64 | 2020-2023 | Xeomin |
| Abbvie INC. | $423.71 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $353.39 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $311.58 | 2020-2022 | |
| Pfizer INC. | $301.78 | 2019-2025 | |
| Lundbeck LLC | $287.18 | 2023-2025 | Rexulti |
| Amgen INC. | $283.64 | 2019-2025 | Repatha, Evenity |
| Novo Nordisk INC | $279.34 | 2019-2021 | |
| Allergan, INC. | $250.56 | 2019-2022 | |
| Amarin Pharma, INC. | $213.19 | 2019-2020 | |
| Esperion Therapeutics, INC. | $205.56 | 2020-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $191.18 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.98 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.89 | 2022-2025 | |
| Tolmar, INC. | $133.45 | 2023-2025 | Jatenzo |
Show all 50 companies
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Flippo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.